Long-term protection of the rat nigrostriatal dopaminergic system by glial cell line-derived neurotrophic factor against 6-hydroxydopamine in vivo - PubMed (original) (raw)

Long-term protection of the rat nigrostriatal dopaminergic system by glial cell line-derived neurotrophic factor against 6-hydroxydopamine in vivo

A M Sullivan et al. Eur J Neurosci. 1998 Jan.

Abstract

Glial cell-line-derived neurotrophic factor (GDNF) has been shown to enhance the survival of dopaminergic neurones both in vitro and in vivo, and to protect the rodent dopaminergic system from neurotoxic damage. However, most previous studies have only examined the short-term protective effects of GDNF. We have investigated the long-term effects of GDNF on a 6-hydroxydopamine (6-OHDA)-induced lesion of the rat medial forebrain bundle (MFB), which results in complete and irreversible destruction of the nigrostriatal pathway, and is a robust model of Parkinson's disease. GDNF was administered ipsilaterally above the substantia nigra and into the lateral ventricle immediately before a unilateral 6-OHDA injection into the MFB. The effects of GDNF were examined in vivo by behavioural testing and positron emission tomography (PET) at weekly intervals, for 12 weeks. GDNF prevented the development of amphetamine-induced rotations at all time-points. PET studies, using [11C]-RTI-121 as a tracer for the dopamine transporter, indicated that GDNF prevented 6-OHDA-induced reduction of dopamine reuptake sites in the ipsilateral striatum. Post-mortem neurochemical analysis at 13 weeks after surgery found that GDNF significantly inhibited 6-OHDA-induced loss of dopamine, 3,4-dihydroxyphenylacetic acid and homovanillic acid in the ipsilateral striatum. Immunocytochemistry showed that GDNF reduced 6-OHDA-induced loss of tyrosine hydroxylase-positive neurones in both the substantia nigra pars compacta and ventral tegmental area. We have shown that a single treatment with GDNF can confer long-term protective effects against a 6-OHDA lesion, which suggests that this factor may be useful for the treatment of Parkinson's disease.

PubMed Disclaimer

Cited by

Clearance and toxicity of recombinant methionyl human glial cell line-derived neurotrophic factor (r-metHu GDNF) following acute convection-enhanced delivery into the striatum.
Taylor H, Barua N, Bienemann A, Wyatt M, Castrique E, Foster R, Luz M, Fibiger C, Mohr E, Gill S. Taylor H, et al. PLoS One. 2013;8(3):e56186. doi: 10.1371/journal.pone.0056186. Epub 2013 Mar 20. PLoS One. 2013. PMID: 23526931 Free PMC article.
Effects of anaesthetics on the loss of nigrostriatal dopaminergic neurons by 6-hydroxydopamine in rats.
Datla KP, Zbarsky V, Dexter DT. Datla KP, et al. J Neural Transm (Vienna). 2006 May;113(5):583-91. doi: 10.1007/s00702-005-0353-x. Epub 2005 Aug 5. J Neural Transm (Vienna). 2006. PMID: 16082506
NME1 Protects Against Neurotoxin-, α-Synuclein- and LRRK2-Induced Neurite Degeneration in Cell Models of Parkinson's Disease.
Anantha J, Goulding SR, Tuboly E, O'Mahony AG, Moloney GM, Lomansey G, McCarthy CM, Collins LM, Sullivan AM, O'Keeffe GW. Anantha J, et al. Mol Neurobiol. 2022 Jan;59(1):61-76. doi: 10.1007/s12035-021-02569-6. Epub 2021 Oct 8. Mol Neurobiol. 2022. PMID: 34623600 Free PMC article.
Comparison of fetal mesencephalic grafts, AAV-delivered GDNF, and both combined in an MPTP-induced nonhuman primate Parkinson's model.
Redmond DE Jr, McEntire CR, Kingsbery JP, Leranth C, Elsworth JD, Bjugstad KB, Roth RH, Samulski RJ, Sladek JR Jr. Redmond DE Jr, et al. Mol Ther. 2013 Dec;21(12):2160-8. doi: 10.1038/mt.2013.180. Epub 2013 Aug 5. Mol Ther. 2013. PMID: 23913185 Free PMC article.
Animal models of neurodegenerative disease: insights from in vivo imaging studies.
Strome EM, Doudet DJ. Strome EM, et al. Mol Imaging Biol. 2007 Jul-Aug;9(4):186-95. doi: 10.1007/s11307-007-0093-4. Mol Imaging Biol. 2007. PMID: 17357857 Review.

Long-term protection of the rat nigrostriatal dopaminergic system by glial cell line-derived neurotrophic factor against 6-hydroxydopamine in vivo - PubMed (original) (raw)